Curium clears patent hurdle to challenge Novartis’s lutetium Lu 177 dotatate monopoly

Boston-based Curium Pharma prevailed in a patent dispute brought by Novartis subsidiary Advanced Accelerator Applications (AAA) before the Delaware US District Court, with the judge ruling that all relevant patent claims asserted by Novartis/AAA are both invalid and not infringed by Curium’s lutetium Lu 177 dotatate product. The complete invalidation removes the principal legal barrier to Curium’s planned US commercial launch of a radioligand therapy for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, a market currently dominated by Novartis’s branded product.

Novartis retains the option to appeal the ruling, and the litigation record does not yet indicate whether AAA intends to do so. Specific patent numbers, expiry dates, and claim language are not disclosed in Curium’s announcement; the full scope of the invalidated claims would require review of the Delaware court docket.

Competitive context for the patent dispute

Novartis’s lutetium Lu 177 dotatate (Lutathera) holds US FDA approval for somatostatin receptor-positive GEP-NETs in adults and has been the sole approved radioligand therapy in this indication since its 2018 clearance. The litigation follows the established Hatch-Waxman pattern in which a follow-on manufacturer challenges originator IP to secure market entry, though the radiopharmaceutical sector operates under a distinct regulatory framework compared with conventional small-molecule generics. Curium’s product uses the same lutetium-177 dotatate radioligand approach as Lutathera, targeting somatostatin receptor-positive tumors.

The patent dispute outcome carries implications for the competitive dynamics of the neuroendocrine tumor therapy market more broadly. A single-source supply environment for lutetium Lu 177 dotatate in the US has constrained patient access in some settings, a concern noted by oncology and nuclear medicine communities. A second approved and commercially available supplier could affect both pricing and treatment center capacity to offer the therapy, though specific commercial terms and launch timing remain undisclosed by Curium.

Curium’s pipeline additionally includes investigational programs in prostate cancer, a segment where Novartis’s lutetium Lu 177 vipivotide tetraxetan (Pluvicto) has established a second commercial radioligand therapy franchise following its 2022 US FDA approval for PSMA-positive metastatic castration-resistant prostate cancer, with that drug’s indication recently extended to pre-chemotherapy use.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/